Investors don't value your IP, they check it

Founders present their IP. Investors then arrive to audit it. The two exercises have almost nothing in common.

A pitch treats IP as many things: evidence of a moat, superior technology, customer benefits, for example. And demonstrates value through filings made, patents granted, territories covered.

Investor diligence treats IP as a risk register. The fund's counsel is not looking for reasons to value the portfolio higher. They are looking for leakage: defects that bleed value. This means scanning for the gaps that can pull down valuations, make the round harder to close, or warranties the founders cannot give, or conditions to be met before money moves.

Venture-ready IP, then, is not necessarily a large or impressive portfolio built on technological wizardry. It is an IP position that survives someone else's vetting process.

That distinction matters more than it first appears, because whatever you say about IP during the raise reappears later as a warranty in the subscription agreement, given by the company and often by the founders personally. The diligence answer and the liability are the same document.

The defects that reprice a round

Most IP diligence findings fall into four categories, in rough order of how often they surface and how much damage they do.

• Ownership gaps. Founder assignments never executed. Contractors who wrote core code under agreements with no present assignment. Background rights held by a university or a prior employer. A co-founder who left before anything was signed. These are the most common finding and the hardest to repair after the fact, because the repair needs cooperation from someone who now holds leverage.
• Disclosure before filing. Demo days, published papers, public repositories, customer trials without confidentiality in place. Australia and the United States offer limited grace periods for an inventor's own disclosure. Europe and China largely do not. One unguarded disclosure can remove the markets that make the plan work.
• Scope that does not match the product. Portfolios often protect the first prototype rather than the current product, and rarely the product a competitor would build to compete. Investors ask whether the claims read on what you sell today. It is a short conversation when the answer is no.
• Encumbrances. Exclusive licences granted early for revenue, grant funding conditions, security interests, open-source obligations buried in a core module. Each one narrows what the company can do with the asset it says it owns.

None of these is usually fatal on its own. All of them move terms: an escrow, a price adjustment, a condition precedent, or a slower close while someone chases a signature.

IP rights you can actually use

Registered IP rights are only worth the leverage those rights create. And leverage turns on two questions investors ask directly.

• Can you detect infringement? A claim directed to an internal server-side process may be perfectly valid and practically unenforceable. That outcome is decided years earlier, at drafting.
• Are the rights in the right places? They need to exist where infringement would occur and where the revenue sits, not only where the company is incorporated.

The realistic posture for a venture-stage company is not litigation. It is negotiation: licensing terms, partnership terms, acquisition price. Rights that are visible, verifiable and correctly placed do that work. Rights that aren't, don't.

Process is the forward indicator

Diligence looks backwards, but investors are underwriting the next five years of asset creation. What tells them most is not the filings already made. It is whether the company has a reliable way of noticing what is worth protecting.

Signals that read well:

• Invention capture tied to release cycles rather than to fundraising cycles
• A live register: asset, owner, status, jurisdiction, next deadline, and the product feature it covers
• A record of what was deliberately not filed, and why

The last one is counterintuitive and carries real weight. A documented decision not to file reads as judgment. Silence reads as absence.

Ready before the term sheet

Assembled early, the following takes a few days. Assembled during diligence, it takes the deal's momentum.

• Executed assignments from every founder, employee and contractor who touched the technology
• A current schedule of registrations and applications, with status and upcoming deadlines
• Licences in and out, including anything attached to grant funding
• An open-source inventory for the shipped codebase
• Trade mark clearance across the markets in the plan, not only the home market
• A short note mapping the two or three rights that matter to the product features that generate revenue

That last item does more than the rest combined. It is the only document in the set that tells an investor what the portfolio is for.

The short version

Investors are not asking whether your IP is impressive. They are asking whether it is owned, unencumbered, correctly scoped, and usable in the places that matter. Those questions have documented answers or they don't, and the time to find out is before someone else asks.